Growing awareness about women health is driving the growth of Global Gynecology Drugs Market in the forecast period 2023-2027.
According to TechSci report on, “Gynecology Drugs Market – Global Industry Size, Share, Trends, Competition, Opportunities and Forecast, 2017-2027” The global gynecology drugs market stood at USD14139.56 million in 2021 and is anticipated to grow at a CAGR of 8.64% in the forecast period. This growth can be attributed to the increasing incidence of gynecological cancer and other diseases. Gynecological drugs treat gynecological cancers, menopausal problems, polycystic ovarian syndrome, contraception, and other illnesses. The global gynecological drugs market is growing due to rising awareness among females about various gynecological disorders and their long-term consequences. The key competitors in the market for gynecological medications are increasingly interested in expanding their product portfolios and distribution networks. These efforts suggest that the global gynecological medicines market could grow from 2017 to 2027.
In the last five years, the fatality rate among women has risen. As a result, governments worldwide are focused on raising awareness and warning women about the importance of monitoring their health and gynecological disorders. These are expected to fuel the market’s expansion in the upcoming years. In addition, market growth is likely to be fueled by changes in women’s lifestyles. As the number of working women in various industries rises, the risk of infection and sickness due to extended exposure to dangerous chemicals and toxins is projected to rise, affecting the worldwide gynecological drugs market.
The increase in the percentage of the elderly female population is expected to boost the global gynecology drugs market during the forecast period. As the population of old females increases, they are projected to be suffering from more gynecological problems. For instance, according to the World Population Prospects, about 9.5% of females above the age group of 60 years as of 2021, from which most of the female population are susceptible to gynecological infections or diseases. So, the increased ratio of the old female population is also enhancing the growth of the gynecology drugs market worldwide.
There has been an increase in the investment in gynecological research by major players such as Roche, Pfizer, Merck, and many others. For instance, in 2019, Merck invested USD125 million in Moderna Therapeutics to support the company in doing gynecological studies and developing personalized vaccines and using precision medicine to treat gynecological disorders and diseases. This, in turn, is expected to support the growth of the global gynecology drugs market during the forecast period.
Browse over 121 market data Figures and 9 market data Tables spread through 199 Pages and an in-depth TOC on “Global Gynecology Drugs Market”.
https://www.techsciresearch.com/report/gynecology-drugs-market/7427.html
Global gynecology drugs market is segmented by therapeutics, indication, distribution channel, region, and company. Based on indication, the market is segmented into contraception, gynecology infections, female infertility, postmenopausal disorders, polycystic ovary syndrome, gynecology cancer, and endometriosis. Contraception holds a major revenue share among the other indications of the increased demand for oral contraceptive drugs due to their clinical benefits over other traditional drugs. Moreover, the government in developing countries is also promoting adopting and using contraceptive drugs to control the rapidly increasing population. Based on the distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. Online pharmacies showed substantial growth during the COVID-19 crisis as many consumers shifted towards e-pharmacies to avoid the risk of infection.
A partial list of leading companies in the global gynecological drugs market includes:
- Amgen Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Bayer AG
- Merck & Co., Inc.
- Eli Lilly and Company
- Pfizer Inc.
- Abbott Laboratories
- AbbVie Inc.
- GlaxoSmithKline Plc
- AstraZeneca Plc
- Lupin Limited
- Johnson and Johnson
- Sanofi SA
- Ferring Pharmaceuticals
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7427
Customers can also request for 10% free customization on this report.
The Asia Pacific region is expected to register significant growth in the global gynecological drugs market during the forecast period. The market is driven by increasing population and economic development, resulting in the expansion of the health care sector. Additionally, improving healthcare infrastructure and increasing initiatives by governments of countries in the region are expected to influence market growth positively. For instance, the National Rural Health Mission is an initiative to increase public expenditure on health, thereby providing better healthcare facilities to females in India. Countries like China, India, and South Korea focus on generating awareness regarding the functions and diseases specific to women and girls, especially those affecting the reproductive system. Besides, high growth in the female population in the region is likely to create lucrative opportunities for market growth in the forthcoming years.
New market players may align themselves with the government authorities to identify the geographies in urgent need of gynecological drugs in the market. Rural population requires well-established healthcare system and thus merger & acquisitions with the global giants to facilitate the infrastructure development would support their brand establishment in the future market,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Gynecology Drugs Market – Global Industry Size, Share, Trends, Competition, Opportunities and Forecast, 2017-2027 Segmented By Therapeutics (Non-Hormonal Therapy vs. Hormonal Therapy), By Indication (Contraception, Gynecology Infections, Female Infertility, Postmenopausal disorders, Polycystic Ovary Syndrome, Osteoporosis, Gynecology Cancer, Endometriosis, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region”, has evaluated the future growth potential of global gynecological drugs market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global gynecology drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]